Fig. 3From: Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan AfricaeDISH (evaluation of drug-induced serious hepatotoxicity) of ALT against bilirubin by cohort and treatment (Safety set)Back to article page